Rifampicin combined regimens for Gram-negative infections: data from the literature

International Journal of Antimicrobial Agents

Volumn 35, Issue 1, 2010, Pages 39-44

  Drapeau, C M J ^a   Grilli, E ^a   Petrosillo, N ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

Author keywords

Combination regimens; Gram negative; Rifampicin; Synergism

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; COLISTIN; ETHAMBUTOL; GENTAMICIN; IMIPENEM; ISONIAZID; MEROPENEM; MONOBACTAM DERIVATIVE; PENICILLIN DERIVATIVE; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SULTAMICILLIN; TIMENTIN; UREIDOPENICILLIN DERIVATIVE; VANCOMYCIN;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ANTIBIOTIC SENSITIVITY; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; GRAM NEGATIVE INFECTION; HUMAN; MEDICAL LITERATURE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; SURVIVAL RATE;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RIFAMPIN; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 70849121220     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2009.08.011     Document Type: Article

References (42)

1. Lee N.Y., Lee H.C., Ko N.Y., Chang C.M., Shih H.I., Wu C.J., et al. Clinical and economic impact of multidrug resistance in nosocomial Acinetobacter baumannii bacteremia. Infect Control Hosp Epidemiol 28 (2007) 713-719
2. Trottier V., Namias N., Pust D.G., Nuwayhid Z., Manning R., Marttos Jr. A.C., et al. Outcomes of Acinetobacter baumannii infection in critically ill surgical patients. Surg Infect (Larchmt) 8 (2007) 437-443
3. Fournier P.E., and Richet H. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis 42 (2006) 692-699
4. Erdem I., Ozgultekin A., Sengoz Inan A., Dincer E., Turan G., Ceran N., et al. Incidence, etiology, and antibiotic resistance patterns of Gram-negative microorganisms isolated from patients with ventilator-associated pneumonia in a medical-surgical intensive care unit of a teaching hospital in Istanbul, Turkey (2004-2006). Jpn J Infect Dis 61 (2008) 339-342
5. Falagas M.E., and Bliziotis I.A. Pandrug-resistant Gram-negative bacteria: the dawn of the post-antibiotic era?. Int J Antimicrob Agents 29 (2007) 630-636
6. Falagas M.E., and Kasiakou S.K. Colistin: the revival of polymyxins for the management of multidrug-resistant Gram-negative bacterial infections. Clin Infect Dis 40 (2005) 1333-1341 [Erratum in: Clin Infect Dis 2006;42:1819]
7. Evans M.E., Feola D.J., Rapp R.P., and Polymyxin. B sulfate and colistin: old antibiotics for emerging multiresistant Gram-negative bacteria. Ann Pharmacother 33 (1999) 960-967
8. Tripodi M.F., Durante-Mangoni E., Fortunato R., Utili R., and Zarrilli R. Comparative activities of colistin, rifampicin, imipenem and sulbactam/ampicillin alone or in combination against epidemic multidrug-resistant Acinetobacter baumannii isolates producing OXA-58 carbapenemases. Int J Antimicrob Agents 30 (2007) 537-540
9. Giamarellos-Bourboulis E.J., Karnesis L., and Giamarellou H. Synergy of colistin with rifampin and trimethoprim/sulfamethoxazole on multidrug-resistant Stenotrophomonas maltophilia. Diagn Microbiol Infect Dis 44 (2002) 259-263
10. Giamarellos-Bourboulis E.J., Xirouchaki E., and Giamarellou H. Interactions of colistin and rifampin on multidrug-resistant Acinetobacter baumannii. Diagn Microbiol Infect Dis 40 (2001) 117-120
11. Yoon J., Urban C., Terzian C., Mariano N., and Rahal J.J. In vitro double and triple synergistic activities of polymyxin B, imipenem, and rifampin against multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 48 (2004) 753-757
12. Tascini C., Ferranti S., Messina F., and Menichetti F. In vitro and in vivo synergistic activity of colistin, rifampin, and amikacin against a multiresistant Pseudomonas aeruginosa isolate. Clin Microbiol Infect 6 (2000) 690-691
13. Tascini C., Menichetti F., Bozza S., Del Favero A., and Bistoni F. Evaluation of the activities of two-drug combinations of rifampicin, polymyxin B and ampicillin/sulbactam against Acinetobacter baumannii. J Antimicrob Chemother 42 (1998) 270-271
14. Landman D., Bratu S., Alam M., and Quale J. Citywide emergence of Pseudomonas aeruginosa strains with reduced susceptibility to polymyxin B. J Antimicrob Chemother 55 (2005) 954-957
15. Hogg G.M., Barr J.G., and Webb C.H. In-vitro activity of the combination of colistin and rifampicin against multidrug-resistant strains of Acinetobacter baumannii. J Antimicrob Chemother 41 (1998) 494-495
16. Korvick J.A., Peacock J.E., Muder R.R., Wheeler R.R., and Yu V.L. Addition of rifampin to combination antibiotic therapy for Pseudomonas aeruginosa bacteremia: prospective trial using Zelen protocol. Antimicrob Agents Chemother 36 (1992) 620-625
17. Loubinoux J., Mihaila-Amrouche L., Le Fleche A., Pigne E., Huchon G., Grimont P.A.D., et al. Bacteremia caused by Acinetobacter ursingii. J Clin Microbiol 41 (2003) 1337-1338
18. Tascini C., Gemignani G., Ferranti S., Tagliaferri E., Leonildi A., Lucarini A., et al. Microbiological activity and clinical efficacy of a colistin and rifampin combination in multidrug-resistant Pseudomonas aeruginosa infections. J Chemother 3 (2004) 282-287
19. Petrosillo N., Chinello P., Proietti M.F., Cecchini L., Masala M., Franchi C., et al. Combined colistin and rifampicin therapy for carbapenem-resistant Acinetobacter baumannii infections: clinical outcome and adverse events. Clin Microbiol Infect 11 (2005) 682-683
20. Gleeson T., Petersen K., and Mascola J. Successful treatment of Acinetobacter meningitis with meropenem and rifampicin. J Antimicrob Chemother 56 (2005) 602-603
21. Sharma A., Shariff M., Thukral S.S., and Shah A. Chronic community-acquired Acinetobacter pneumonia that responded slowly to rifampicin in the anti-tuberculous regime. J Infect 51 (2005) e149-e152
22. Saballs M., Pujol M., Tubau F., Pena C., Montero A., Angeles Dominguez M., et al. Rifampicin/imipenem combination in the treatment of carbapenem-resistant Acinetobacter baumannii infections. J Antimicrob Chemother 58 (2006) 697-700
23. Motaouakkil S., Charra B., Hachimi A., and Benslama A. Nosocomial pneumonia caused by multiresistant Acinetobacter baumannii treated by colistin and rifampicin [in French]. Ann Fr Anesth Reanim 25 (2006) 543-544
24. Tascini C., Menichetti F., Gemignani G., Palumbo F., Leonildi A., Tedeschi A., et al. Clinical and microbiological efficacy of colistin therapy in combination with rifampin and imipenem in multidrug-resistant Pseudomonas aeruginosa diabetic foot infection with osteomyelitis. Int J Low Extrem Wounds 5 (2006) 213-216
25. Tascini C., Gemignani G., Palumbo F., Leonildi A., Tedeschi A., Lambelet P., et al. Clinical and microbiological efficacy of colistin therapy alone or in combination as treatment for multidrug resistant Pseudomonas aeruginosa diabetic foot infections with or without osteomyelitis. J Chemother 6 (2006) 648-651
26. Ostronoff M., Ostronoff F., Sucupira A., Souto Maior A.P., Caniza M., Florêncio R., et al. Multidrug-resistant Pseudomonas aeruginosa infection in neutropenic patients successfully treated with a combination of polymyxin B and rifampin. Int J Infect Dis 10 (2006) 339-340
27. Memikoglu K.O., Alver Alkaya F., Koken Z., Serdaroglu H., Cakir T., and Azap A. Successful treatment of multidrug-resistant Acinetobacter baumannii meningitis with colistin and rifampicin. Seventeenth European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)/25th International Congress of Chemotherapy (ICC); 31 March-3 April 2007, Munich, Germany (2007) 214 [Poster S332]
28. Rodriguez Guardado A., Asensi V., Lantero M., Castillo M., and Carton J. Multidrug-resistant Acinetobacter baumannii prosthetic joint infection treated with colistin. Seventeenth European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)/25th International Congress of Chemotherapy (ICC); 31 March-3 April 2007; Munich, Germany (2007) 1345 [Poster S372]
29. Biancofiore G., Tascini C., Bisà M., Gemignani G., Bindi M.L., Leonildi A., et al. Colistin, meropenem and rifampin in a combination therapy for multidrug-resistant Acinetobacter baumannii multifocal infection. Minerva Anestesiol 73 (2007) 181-185
30. Totsugawa T., Kuinose M., Yoshitaka H., Tsushima Y., Ishida A., and Minami H. Mycotic aortic aneurysm induced by Klebsiella pneumoniae successfully treated by in-situ replacement with rifampicin-bonded prosthesis: report of 3 cases. Circ J 71 (2007) 1317-1320
31. Bassetti M., Repetto E., Righi E., Boni S., Diverio M., Molinari M.P., et al. Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections. J Antimicrob Chemother 61 (2008) 417-420
32. Young Song J., Lee J., Yeon Heo J., Yun Noh J., Joo Kim, and Jin Cheong H. Colistin and rifampicin combination in the treatment of ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii. Int J Antimicrob Agents 32 (2008) 281-284
33. VIM-1 metallo-β-lactamase-producing Enterobacter cloacae disseminated infection in a liver transplant patient. Minerva Anestesiol 74 (2008) 47-49
34. Marques M.B., Brookings E.S., Moser S.A., Sonke P.B., and Waites K.B. Comparative in vitro antimicrobial susceptibilities of nosocomial combinations. Antimicrob Agents Chemother 41 (1997) 881-885
35. Xiao Y.H., and Wang Y.L. Bacterial resistance surveillance in China: a report from Mohnarin 2004-2005. Eur J Clin Microbiol Infect Dis 27 (2008) 697-708
36. Franchi C., Venditti M., Rocco M., Spadetta G., Vullo V., Raponi M., et al. Microbiological surveillance in an intensive care unit of a large Roman hospital. Infez Med 10 (2002) 93-99 [in Italian]
37. Savage P.B. Multidrug-resistant bacteria: overcoming antibiotic permeability barriers of Gram-negative bacteria. Ann Med 33 (2001) 167-171
38. Vaara M. Agents that increase the permeability of the outer membrane. Microbiol Rev 56 (1992) 395-411
39. Wehrli W. Rifampin: mechanism of action and resistance. Rev Infect Dis 5 Suppl. 3 (1983) S407-S411
40. Yau W., Owen R.J., Poudyal A., Bell J.M., Turnidge J.D., Yu H.H., et al. Colistin hetero-resistance in multidrug-resistant Acinetobacter baumannii clinical isolates from the Western Pacific region in the SENTRY antimicrobial surveillance programme. J Infect 58 (2009) 138-144
41. Montero A., Ariza J., Corbella X., Doménech A., Cabellos C., Ayats J., et al. Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model. J Antimicrob Chemother 54 (2004) 1085-1091
42. Pantopoulou A., Giamarellos-Bourboulis E.J., Raftogannis M., Tsaganos T., Dontas I., Koutoukas P., et al. Colistin offers prolonged survival in experimental infection by multidrug-resistant Acinetobacter baumannii: the significance of co-administration of rifampicin. Int J Antimicrob Agents 29 (2007) 51-55